Spontaneous diaphragmatic rupture following neoadjuvant chemoterapy and cytoreductive surgery in malignant pleural mesothelioma: a case report and review of the literature
Publication date: Available online 16 September 2020Source: International Journal of Surgery Case ReportsAuthor(s): Margherita Cattaneo, Paolo Mendogni, Francesco Damarco, Davide Tosi
ConclusionsRadiological early MPM occurs in approximately 1 of every 20 patients treated with neoadjuvant chemotherapy and surgery planned at the time of diagnosis in an experienced center. Radiological early MPM was associated with early pathological stage and long-term survival.
Authors: Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T Abstract Objective: The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers. Methods: The guideline was developed by the Program in Evidence-Based Care together with the Surgical Oncology Program at Ontario Health (Cancer Care Ontario) through a systematic review of relevant literature, patient- and caregiver-specific consultation, and internal and external reviews. Results: Re...
Neoadjuvant chemotherapy — often used before aggressive surgery — has shown no definitive survival benefit for patients with pleural mesothelioma cancer, according to a recent study at the Duke University Medical Center. The study strengthened the growing belief among mesothelioma specialists that the combination of chemotherapy drugs cisplatin and pemetrexed might be a more effective treatment after surgery than before. “I think the study provides a little more evidence to support what those of us were seeing, that
Conclusions: SMART provided promising oncologic outcomes at the cost of significant treatment related morbidity. Due to the significant treatment associated morbidity and favorable treatment alternatives, we have not broadly adopted SMART at our institution.
CONCLUSIONS: The pPCI strongly differs from the sPCI for patients undergoing CRS for peritoneal disease and may provide a more accurate evaluation of the peritoneal disease extent. Further studies are needed to determine its prognostic value compared with sPCI, and consensus guidelines are needed for calculating it. PMID: 32040698 [PubMed - as supplied by publisher]
ConclusionsPost-recurrence survival after pleurectomy/decortication is acceptable, and post-recurrence treatment, performance status, and disease-free interval are important prognostic factors of post-recurrence survival.
CONCLUSIONS: Post-recurrence survival after pleurectomy/decortication is acceptable, and post-recurrence treatment, performance status, and disease-free interval are important prognostic factors of post-recurrence survival. PMID: 31962118 [PubMed - as supplied by publisher]
Conclusion: This is the first description of gC1qR expression in MPM. The data identify gC1qR as a potential new prognostic factor in patients treated with surgery and chemotherapy.
Authors: Kuribayashi K, Doi H, Kijima T Abstract Introduction: The surgical arm of the Mesothelioma and Radical Surgery (MARS) trial involved a multimodal approach, with combined therapy consisting of chemotherapy, complete gross resection, and radiation therapy. However, the MARS trial did not compare surgery with chemotherapy, and the survival and quality of life outcomes of this trial's surgical arm were inferior to those of the non-surgical arm. Methods for achieving complete gross resection (macroscopic complete response [MCR]) include extrapleural pneumonectomy (EPP), wherein the pleura, lung, diaphragm, and ...
Malignant pleural mesothelioma (MPM) is a locoregionally aggressive malignancy with dismal outcomes. Trimodality therapy including neoadjuvant chemotherapy, surgical resection, and adjuvant radiotherapy (RT) is associated with a survival benefit in selected patients.1,2 However, 50% to 60% of patients are unable to complete trimodality treatment —resection is deferred because of disease progression during chemotherapy, and RT is deferred because of postoperative complications.3 In their article in this issue of the Journal, Nelson and colleagues4 explore factors affecting the likelihood of returning to RT after surgi...